Multi-parameter lead optimization to give an oral CHK1 inhibitor clinical candidate: (R)-5-((4-((morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737)


Select a different viewer

Citation:

See Citation Policies for referencing Mol*, RCSB PDB, PDB structures, and Computed Structure Models.